Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Adaptive Androgen Deprivation Therapy (ADT) plus Standard of Care. The purpose of this study
is to develop adaptive therapy for high risk metastatic castration sensitive prostate cancer
(mCSPC).
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute